Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

25 oct. 2016 07h45 HE | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Fast Track Designation from FDA for ABO-102 in Sanfilippo Syndrome Type A

NEW YORK, NY and CLEVELAND, OH--(Marketwired - October 25, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for...
20 oct. 2016 07h43 HE | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at Orphan Drugs & Rare Disease Conference, London UK

NEW YORK, NY and CLEVELAND, OH--(Marketwired - October 20, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO):ABO-102 gene therapy well-tolerated at low-dose Cohort of 3 subjects Significant average...
18 oct. 2016 07h45 HE | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-102 Gene Therapy in Sanfilippo Syndrome Type A

NEW YORK, NY, and CLEVELAND, OH--(Marketwired - October 18, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical- stage biopharmaceutical company focused on developing gene therapies for...
14 oct. 2016 07h03 HE | Source: Abeona Therapeutics Inc.

Abeona Therapeutics to Present Top-Line Data of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients at Upcoming Orphan Drugs and Rare Disease Congress October 19-20th in London, UK

NEW YORK, NY and CLEVELAND, OH--(Marketwired - October 14, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing gene therapies for...
07 oct. 2016 09h19 HE | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Publication of Preclinical Data Supporting Clinical Translation of Juvenile Batten Disease Gene Therapy

NEW YORK, NY and CLEVELAND, OH--(Marketwired - October 07, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO):Preclinical efficacy data demonstrated corrected motor deficits, attenuated...
05 oct. 2016 07h03 HE | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Data Safety Monitoring Board Approves ABO-102 Dose Escalation for Second Cohort in Phase 1/2 Clinical Trial for Sanfilippo Syndrome Type A

NEW YORK, NY and CLEVELAND, OH--(Marketwired - October 05, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO)ABO-102 (AAV-SGSH) delivers first-in-man AAV-based gene therapy administered by single...
04 oct. 2016 07h03 HE | Source: Abeona Therapeutics Inc.

Abeona Therapeutics to Present at Jefferies Gene Editing & Gene Therapy Summit

NEW YORK, NY and CLEVELAND, OH --(Marketwired - October 04, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for...
29 sept. 2016 07h03 HE | Source: Abeona Therapeutics Inc.

Abeona Therapeutics to Present at Cell Gene Meeting on the Mesa

NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 29, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for...
26 sept. 2016 07h03 HE | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Enrolls First Patient in Phase 2 for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa

NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 26, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) Phase 1 clinical trial in five patients demonstrated EB-101 (gene corrected skin grafts)...
23 sept. 2016 07h03 HE | Source: Abeona Therapeutics Inc.

Abeona Therapeutics to Present at Ladenburg Thalmann 2016 Healthcare Conference

NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 23, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for...

Page précédente

Page suivante